Basic Information
SAQUIN SR PROLONGED-RELEASE TABLETS 150mg
TABLET, EXTENDED RELEASE
Regulatory Information
SIN16690P
February 14, 2023
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XN05AH04
Company Information
MANSA HEALTHCARE PTE. LTD.
MANSA HEALTHCARE PTE. LTD.
Active Ingredients
Strength: 150.000mg
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.
Indication Information
**4.1 Therapeutic indications** Saquin SR is indicated for: - Treatment of Schizophrenia - Treatment of bipolar disorder: - For the treatment of manic episodes associated with bipolar I disorder - For the treatment of depressive episodes associated with bipolar disorder - For the prevention of recurrence in maintenance treatment of bipolar disorder (manic, mixed or depressive episode) as monotherapy or in combination with lithium or valproate - Add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Prior to initiating treatment, clinicians should consider the safety profile of quetiapine.